ArticleMolecular cancer therapeutics2013

Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.

Cale D Fahrenholtz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.